Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...

OMEICOS, a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and inflammatory disorders, announced the successful conclusion of its multi ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod ...

The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...

Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or ...

Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR ...

A dual cross-linked magnetic polymer solves the fundamental trade-off limiting soft artificial muscles, achieving ...

Perimenopause and menopause have finally moved into the public spotlight. While this long-overdue attention has helped many women feel less alone, it has also led to a surge of misinformation.

Certain of AIM’s leadership have indicated to the Company on a non-binding basis that they intend to participate in the Rights Offering, including Board member and Chief Executive Officer Thomas K.

Neurophos is developing a massive optical systolic array clocked at 56GHz good for 470 petaFLOPS of FP4 compute As Moore's ...

As of Wednesday, January 28, Skyworks Solutions, Inc.’s SWKS share price has dipped by 6.90%, which has investors questioning ...